Outpatiented · Case Knowledge
Everything hurts. Not a specific joint from an injury. Everything, diffusely, unpredictably. Maybe worse in the morning. Maybe worse after certain foods. Your doctor ran an inflammatory panel, maybe a rheumatology workup. Everything came back normal or borderline. You were told it might be fibromyalgia or stress. Neither of those is a cause. They are categories. The cause is somewhere in the physiology, and it was not looked for in the right places.
Why Normal Tests Do Not Mean Normal
A standard pain and rheumatology workup typically includes CRP, ESR (inflammation markers), ANA (antinuclear antibody for lupus and related conditions), RF (rheumatoid factor), CBC, and a basic metabolic panel. If these are normal or minimally elevated, the workup is considered complete.
This panel rules out active high-grade inflammation, overt lupus, seropositive rheumatoid arthritis, and significant metabolic abnormalities. It does not rule out chronic low-grade inflammation below the CRP detection threshold for standard assays, seronegative autoimmune conditions (where antibodies are not elevated despite active disease), food sensitivity-driven inflammation, gut permeability-driven systemic inflammatory load, vitamin D deficiency-driven myalgia, early autoimmune disease that has not yet crossed diagnostic thresholds, or post-infectious pain syndromes.
The ANA is positive in 5 percent of the general healthy population and is not diagnostic of anything without clinical context. A negative ANA does not rule out autoimmune-mediated pain. A normal CRP using standard assays does not rule out the chronic low-grade inflammation measured by high-sensitivity CRP.
Normal tests did not find anything.
They were not looking in the right places.
What Is Actually Causing It
Each of the following produces real, measurable pain through a documented physiological mechanism. Most are not investigated on a standard pain workup.
The intestinal lining is a single-cell-thick barrier that controls what enters systemic circulation. When this barrier is compromised (intestinal permeability, colloquially called leaky gut), bacterial fragments, partially digested food proteins, and microbial toxins enter the bloodstream. The immune system responds to these foreign particles with a systemic inflammatory response. This inflammation is low-grade, chronic, and diffuse. It does not typically elevate standard CRP above the detection threshold, but it does produce musculoskeletal pain, fatigue, brain fog, and skin symptoms. High-sensitivity CRP (hs-CRP) can identify this level of inflammation. Intestinal permeability is increased by chronic NSAID use (ironically, the drugs commonly used to treat the pain), alcohol, gluten in genetically susceptible individuals, stress, dysbiosis, and low-fiber diets.
Food sensitivities (distinct from allergies) produce inflammatory responses through IgG-mediated and non-immune mechanisms that do not appear on standard allergy testing. The most documented pain-relevant food sensitivities involve gluten, dairy proteins, nightshades (tomatoes, peppers, eggplant, potatoes), and corn. Gluten sensitivity without celiac disease (non-celiac gluten sensitivity) is associated with widespread pain, fatigue, and cognitive symptoms. Nightshade sensitivity is associated with joint pain and worsening inflammatory conditions in susceptible individuals through alkaloid-mediated intestinal permeability effects. Pain that is worse after specific meals, that improves during periods of dietary restriction, or that varies unpredictably in a pattern that tracks loosely with food is worth investigating through elimination and reintroduction.
Severe vitamin D deficiency causes osteomalacia, which produces diffuse bone and muscle pain. But even moderate deficiency below 30 to 40 ng/mL produces musculoskeletal pain through effects on muscle fiber function, calcium metabolism in muscle cells, and inflammatory regulation. Multiple studies have shown that patients diagnosed with fibromyalgia have significantly higher rates of vitamin D deficiency than the general population, and that vitamin D supplementation reduces pain scores in deficient patients. A person with widespread pain and a vitamin D level of 18 ng/mL (reported as normal by the lab) may have vitamin D-deficient musculoskeletal pain. This is inexpensive to test and inexpensive to treat. It is almost never the first thing checked.
Autoimmune conditions like rheumatoid arthritis, lupus, ankylosing spondylitis, and psoriatic arthritis can produce widespread pain and fatigue for years before serum antibodies rise to diagnostic levels. Seronegative rheumatoid arthritis (RF and anti-CCP negative) is a documented entity accounting for approximately 20 percent of RA diagnoses. Early lupus may have a negative ANA on standard testing before antibody production reaches detectable levels. Ankylosing spondylitis causes inflammatory back pain that can persist for years before HLA-B27 is checked or sacroiliitis appears on imaging. The pattern of pain (worse in the morning and with rest, improving with movement, associated with stiffness lasting more than 30 minutes) points toward inflammatory joint disease that warrants more specific evaluation even with negative initial antibody screens.
Fibromyalgia is a clinical diagnosis defined by widespread pain, fatigue, and specific tender points or widespread pressure pain sensitivity. It is a real condition involving central sensitization, where the nervous system processes pain signals with amplified intensity. What it is not is a complete explanation. Central sensitization in fibromyalgia frequently has an upstream driver: gut dysbiosis, chronic low-grade inflammation, autoimmune activity, sleep disruption (specifically non-restorative sleep that disrupts pain threshold regulation), trauma history, or vitamin D deficiency. The fibromyalgia label ends the diagnostic process for most patients and leads to pain management rather than root cause investigation. Research on fibromyalgia consistently shows gut microbiome abnormalities, elevated inflammatory markers on sensitive assays, sleep architecture disruption, and HPA axis dysregulation compared to controls.
Post-infectious pain syndromes are documented after multiple organisms including Borrelia (Lyme disease), Epstein-Barr virus, COVID-19, and others. Lyme disease in particular has a complex and contested diagnostic landscape. The standard two-tier testing (ELISA followed by Western blot) has documented sensitivity limitations, particularly for early infection and for seronegative or seroconversion-phase presentations. Post-Lyme syndrome with ongoing pain, fatigue, and cognitive symptoms occurs in a subset of patients after completed antibiotic treatment through mechanisms including immune dysregulation and possible persistent antigen. Widespread pain that began clearly after a tick exposure, a febrile illness, or a viral syndrome deserves a specific post-infectious evaluation, not a fibromyalgia label by default.
NSAIDs (ibuprofen, naproxen, aspirin, diclofenac) are among the most commonly used treatments for joint and muscle pain. They reduce prostaglandin-mediated inflammation and provide genuine short-term pain relief.
Long-term and high-dose NSAID use increases intestinal permeability. The same prostaglandins that drive inflammation also maintain the integrity of the intestinal mucosal barrier. When NSAIDs suppress prostaglandins throughout the body, the gut barrier is compromised. Bacterial fragments and food antigens enter systemic circulation, triggering the immune-mediated systemic inflammation described above.
A person taking daily ibuprofen for widespread pain may be treating the downstream symptom while worsening the gut permeability that is driving the upstream inflammatory load. The pain relief is real. The contribution to the underlying cause is also real. This is almost never discussed.
Questions People Actually Ask
Why do I ache all over when nothing shows on tests?
Widespread pain with normal standard tests most commonly reflects one of several mechanisms that standard tests are not designed to detect. The most common are chronic low-grade systemic inflammation from gut permeability (below the threshold of standard CRP but detectable by high-sensitivity CRP), food sensitivity-driven inflammation (not detectable on allergy panels), vitamin D deficiency-driven musculoskeletal pain (the lab's normal cutoff of 20 ng/mL does not reflect adequate levels for muscle and bone function), early or seronegative autoimmune disease before antibodies reach diagnostic levels, and fibromyalgia-pattern central sensitization with an unidentified upstream driver.
A normal standard panel does not rule out any of these. It rules out a specific, narrow set of conditions at specific thresholds.
Can gut health cause joint pain?
Yes, through intestinal permeability and systemic immune activation. When the gut lining is compromised, bacterial fragments and food antigens enter systemic circulation. The immune system responds with a diffuse inflammatory response that affects joints, muscles, and connective tissue. This is the mechanism behind reactive arthritis, where gut or urogenital infection triggers joint inflammation, and it is a component of the inflammatory burden in many people with unexplained widespread pain.
Food sensitivities (gluten, dairy, nightshades) produce gut-mediated inflammatory responses that manifest as joint pain in susceptible individuals. The pain often improves with elimination diets and worsens with reintroduction of the triggering food. Standard allergy panels do not detect these sensitivities.
Can vitamin D deficiency cause body aches?
Yes. Vitamin D deficiency at severe levels causes osteomalacia, which produces diffuse bone and muscle pain. At moderate deficiency levels (below 30 to 40 ng/mL), musculoskeletal pain is a documented feature through effects on muscle fiber function and inflammatory regulation.
Multiple studies have found high rates of vitamin D deficiency in fibromyalgia patients, and supplementation trials show meaningful pain reduction in deficient patients. A person with widespread pain and a vitamin D level of 22 ng/mL (inside the lab's normal range) deserves a trial of supplementation to see if the pain responds before the fibromyalgia label becomes permanent.
What is fibromyalgia and what actually causes it?
Fibromyalgia is a clinical syndrome defined by widespread pain, fatigue, and pressure pain sensitivity. The underlying mechanism is central sensitization: the nervous system processes pain signals with amplified intensity, so stimuli that would produce mild discomfort produce significant pain.
What drives the central sensitization is less discussed. Research consistently identifies gut microbiome abnormalities, elevated inflammatory markers on sensitive assays, non-restorative sleep (which disrupts pain threshold regulation through growth hormone and substance P pathways), HPA axis dysregulation, and in many cases a history of physical or psychological trauma as upstream contributors.
The fibromyalgia label is accurate as a description of a pain pattern. It is not a complete explanation of why the central sensitization developed, and stopping at the label stops the investigation into causes that may be addressable.
The MAP Tool maps your pain pattern, your diet, your gut history, and your inflammation picture to root cause. Not a fibromyalgia label and a pain management referral. A thread that goes somewhere real.
Start Your Map